

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	NeuroScientific Biopharmaceuticals Limited
ABN	13 102 832 995

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Brian Leedman
Date of last notice	31 July 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	As director and shareholder of Tasstech Pty Ltd
Date of change	15 January 2021
No. of securities held prior to change	<u>Direct:</u> 1,838,130 Ordinary shares 250,000 Class C Performance Shares 250,000 Class D Performance Shares 250,000 Class E Performance Shares 700,000 Listed options (exercisable at \$0.20 on or before 7 March 2021) 1,200,000 Unlisted options (exercisable at \$0.30 on or before 17 December 2022) <u>Indirect:</u> 91,875 Ordinary shares
Class	Ordinary Shares, unlisted options and performance

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Number acquired	Direct: 500,000 Unlisted Options (exercisable at \$0.40 on or before 15 January 2024)
Number disposed	Direct: n/a Indirect: n/a
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Direct: \$nil Indirect: \$nil
No. of securities held after change	Direct: 1,838,130 Ordinary shares 250,000 Class C Performance Shares 250,000 Class D Performance Shares 250,000 Class E Performance Shares 700,000 Listed options (exercisable at \$0.20 on or before 7 March 2021) 1,200,000 Unlisted options (exercisable at \$0.30 on or before 17 December 2022) Indirect: 91,875 Ordinary shares 500,000 Unlisted Options (exercisable at \$0.40 on or before 15 January 2024)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Allocation of remuneration-based options

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	-
Nature of interest	-
Name of registered holder (if issued securities)	-
Date of change	-

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	-
Interest acquired	-
Interest disposed	-
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	-
Interest after change	-

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a

⁺ See chapter 19 for defined terms.